Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Outlook Therapeutics Inc.

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Outlook Therapeutics, with a price target of $1.00. Accor...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OTLK	$1.88	0.00%	2.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OTLK	$1.88	0%	2.17M
3
4
5
6

OTLK

OTLK

Dividend Overview

Get Outlook Therapeutics Inc. Data in Excel

Get Outlook Therapeutics Inc. Data in Excel